Figure 4.

The HBDs of IGFBP-2 suppress body fat mass gain and prevent the loss of body lean mass in IGFBP-2^−/− mice. IGFBP-2^−/− mice were treated as described in the legend to Figure 3. Body fat and lean mass from each group were analyzed using Echo MRI scanning at weeks 0 and 12, respectively. The changes in total fat mass or lean mass between weeks 0 and 12 in each group are presented as the changes in fat or lean mass expressed as a percentage of body weight (A and B). Each bar value represents mean ± SE. *, P < .05 indicates a significant difference between 2 treatments.